Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.

Antonello VecciaMariachiara DipasqualeStefania KinspergherSara MonteverdiSalvatore GirlandoMattia BarbareschiOrazio Caffo

Published in: Targeted oncology (2022)

Our data confirmed that KRAS mutational status is not associated with survival and response outcomes in advanced non-squamous NSCLC patients treated with immunotherapy alone or combined with chemotherapy.

Keyphrases

high grade
wild type
low grade
small cell lung cancer
electronic health record
locally advanced
advanced non small cell lung cancer
big data
free survival
type diabetes
data analysis
rectal cancer
skeletal muscle
glycemic control
epidermal growth factor receptor
tyrosine kinase